Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | DKK1 | O94907 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15740505 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL15740731 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL29958815 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL30733190 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL22464585 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL19015477 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL16374375 | 1.00 | EGFR (0.50) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL23578784 | 0.91 | EGFR (0.44) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL29959233 | 0.91 | EGFR (0.44) | EGFRKDM1APDE4DDYRK1AHRH3 | |
| SCHEMBL30848738 | 0.91 | EGFR (0.44) | EGFRKDM1APDE4DDYRK1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345329-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | VORONOI INC (KR) | 2025-11-13 | — | — | US | disclosed |
| CN-119630653-A | Heteroaryl derivative compounds and uses thereof | 株式会社沃若诺伊 | 2025-03-14 | — | — | CN | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-117916232-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2023071998-A1 | NOVEL PYRIDO OR TRIAZINE-SUBSTITUTED PYRIDO HETEROCYCLIC COMPOUND | 杭州德睿智药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2022271749-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022271612-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4081515-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | Blueprint Medicines Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345329-A1 | HETEROARYL DERIVATIVE COMPOUND AND USES THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDM1A 4499/4885PDE4D 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.